Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Amortizatization of Intangibles (2022 - 2025)

Historic Amortizatization of Intangibles for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to $517000.0.

  • Zentalis Pharmaceuticals' Amortizatization of Intangibles fell 6857.14% to $517000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year decrease of 6658.6%. This contributed to the annual value of $8.0 million for FY2024, which is 3918.07% down from last year.
  • Zentalis Pharmaceuticals' Amortizatization of Intangibles amounted to $517000.0 in Q3 2025, which was down 6857.14% from $781000.0 recorded in Q2 2025.
  • Over the past 5 years, Zentalis Pharmaceuticals' Amortizatization of Intangibles peaked at $4.6 million during Q4 2023, and registered a low of -$146000.0 during Q1 2022.
  • Over the past 4 years, Zentalis Pharmaceuticals' median Amortizatization of Intangibles value was $1.6 million (recorded in 2024), while the average stood at $1.8 million.
  • In the last 5 years, Zentalis Pharmaceuticals' Amortizatization of Intangibles surged by 239767.44% in 2023 and then crashed by 6933.04% in 2024.
  • Zentalis Pharmaceuticals' Amortizatization of Intangibles (Quarter) stood at $2.5 million in 2022, then surged by 83.97% to $4.6 million in 2023, then plummeted by 69.33% to $1.4 million in 2024, then tumbled by 62.99% to $517000.0 in 2025.
  • Its Amortizatization of Intangibles stands at $517000.0 for Q3 2025, versus $781000.0 for Q2 2025 and $1.0 million for Q1 2025.